Evidence map›Paper›PMID 39315702›Full record

ArticleNucleic acids research2024

FRAME: flap endonuclease 1-engineered PAM module for precise and sensitive modulation of CRISPR/Cas12a trans-cleavage activity.

Tongshan Zuo, Chen Shen, Zhen Xie, Guanhong Xu, Fangdi Wei, Jing Yang, Xiaolei Zhu, Qin Hu, Zheng Zhao, Ben Zhong Tang and 1 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tongshan ZuoSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Chen ShenSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Zhen XieSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Guanhong XuSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Fangdi WeiSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Jing YangSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Xiaolei ZhuDepartment of Neurology, Drum Tower Hospital, Nanjing University, Nanjing, Jiangsu 210008, China.
Qin HuSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Zheng ZhaoClinical Translational Research Center of Aggregation-Induced Emission, School of Medicine, The Second Affiliated Hospital, School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Guangdong 518172, China.ORCID 0000-0002-5536-0439
Ben Zhong TangClinical Translational Research Center of Aggregation-Induced Emission, School of Medicine, The Second Affiliated Hospital, School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Guangdong 518172, China.
Yao CenSchool of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 211166, China.ORCID 0000-0002-7829-979X

Funding

"Blue Project" Foundation of the Higher Education Institutions of Jiangsu ProvinceJiangsu Provincial Health Commission Z2021067Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research, Ministry of EducationNational Natural Science Foundation of China 81973283Natural Science Foundation of Jiangsu Province BK20221304
6 · The paper itself

Abstract

CRISPR/Cas12a system, renowned for its precise recognition and efficient nucleic acid cleavage capabilities, has demonstrated remarkable performance in molecular diagnostics and biosensing. However, the reported Cas12a activity regulation methods often involved intricate CRISPR RNA (crRNA) structural adjustments or costly chemical modifications, which limited their applications. Here, we demonstrated a unique enzyme activity engineering strategy using flap endonuclease 1 (FEN1) to regulate the accessibility of the protospacer adjacent motif (PAM) module in the double-stranded DNA activator (FRAME). By identifying the three-base overlapping structure between the target inputs and substrate, FEN1 selectively cleaved and released the 5'-flap containing the 'TTTN' sequence, which triggered the secondary cleavage of FEN1 while forming a nicked PAM, ultimately achieving the sensitive switching of Cas12a's activity. The FRAME strategy exemplified the 'two birds with one stone' principle, as it not only precisely programmed Cas12a's activity but also simultaneously triggered isothermal cyclic amplification. Moreover, the FRAME strategy was applied to construct a sensing platform for detecting myeloperoxidase and miR-155, which demonstrated high sensitivity and specificity. Importantly, it proved its versatility in detecting multiple targets using a single crRNA without redesign. Collectively, the FRAME strategy opens up a novel avenue for modulating Cas12a's activity, promising immense potential in the realm of medical diagnostics.

Indexed as

CRISPR-Associated ProteinsCRISPR-Cas SystemsFlap EndonucleasesBacterial ProteinsDNAEndodeoxyribonucleasesHumansMicroRNAsPeroxidaseBacterial ProteinsCas12a proteinCRISPR-Associated ProteinsDNAEndodeoxyribonucleasesFlap EndonucleasesMicroRNAsPeroxidase

Identifiers

PMID39315702
PMCPMC11514456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.